Screening asymptomatic patients with diabetes for unknown coronary artery disease: does it reduce risk? An open-label randomized trial comparing a strategy based on exercise testing aimed at revascularization with management based on pharmacological/behavioural treatment of traditional risk factors. DADDY-D Trial (Does coronary Atherosclerosis Deserve to be Diagnosed and treated early in Diabetics?)

Fabrizio Turrini, Roberto Messora, Paolo Giovanardi, Stefano Tondi, Paolo Magnavacchi, Rita Cavani, Giandomenico Tosoni, Carlo Cappelli, Elisa Pellegrini, Stefania Romano, Augusto Baldini, Romeo Giulietto Zennaro, Marco Bondi, Fabrizio Turrini, Roberto Messora, Paolo Giovanardi, Stefano Tondi, Paolo Magnavacchi, Rita Cavani, Giandomenico Tosoni, Carlo Cappelli, Elisa Pellegrini, Stefania Romano, Augusto Baldini, Romeo Giulietto Zennaro, Marco Bondi

Abstract

Background: Coronary artery disease is the leading cause of morbidity and mortality in patients with type 2 diabetes. Screening for asymptomatic coronary artery disease with treatment by means of revascularization seems to be an appealing option for prevention. The utility of such a strategy has never been challenged in a randomized trial.

Methods/design: In the present study a cohort of diabetic patients without any symptoms and without known coronary artery disease will be screened at two diabetes outpatients services. Those with intermediate or high risk (equal or greater than 10% according to the Italian risk chart) will be asked to participate and enrolled. They will be seen and followed in order to provide the best adherence to medical therapy. Half of the patients will be randomized to undergo an exercise tolerance testing while the other group will continue to be regularly seen at diabetes outpatients services. Best medical/behavioral therapy will be offered to both groups. Those patients with a positive exercise tolerance testing will be studied by coronary angiography and treated according to the severity of coronary lesions by percutaneous stenting or surgery.The objective of the study is to evaluate the efficacy of the screening strategy aimed at revascularization. A cost-effectiveness analysis will be performed at the end of the follow up.

Discussion: The study will provide useful information about prevention and treatment of diabetic patients at high risk of coronary events. It will be made clearer if detection of silent coronary artery disease has to be recommended and followed by treatment. Given the simplicity of the study protocol, it will be easily transferable to the real world.

Trial registration: (ClinicalTrials.gov): NCT00547872.

Figures

Figure 1
Figure 1
DADDY-D Trial Flow Chart.

References

    1. Fein F, Scheur J. In: Heart disease in diabetes mellitus: theory and practice. Rifkin H, Porte D Jr, editor. New York: Elsevier; 1990. pp. 812–823.
    1. Bonow RO, Bohannon N, Hazzard W. Risk stratification in coronary artery disease and special populations (review) Am J Med. 1996;101:17S–22S. doi: 10.1016/S0002-9343(96)00312-9.
    1. Jouven X, Lemaitre RN, Rea TD, Sotoodehnia N, Empana JP, Siscovick DS. Diabetes, glucose level, and risk of sudden cardiac death. Eur Heart J. 2005;26:2142–2147. doi: 10.1093/eurheartj/ehi376.
    1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234. doi: 10.1056/NEJM199807233390404.
    1. Greenland P, Lloyd-Jones D. Definign a rational approach to screening for cardiovascular risk in asymptomatic patients. J Am Coll Card. 2008;52:330–332. doi: 10.1016/j.jacc.2008.04.029.
    1. Bax JJ, Inzucchi SE, Bonow RO, Schiuf JD, Freeman MR, Barrett EJ. Cardiac Imaging for risk stratification in diabetes. Diabetes Care. 2007;30:1295–1304. doi: 10.2337/dc06-2094.
    1. Beller GA. Noninvasive screening for coronary atheroscelrosis and silent ischemia in asymptomatic type 2 diabetic patients: is it appropriate and cost-effective? J Am Coll Card. 2007;49:1918–1923. doi: 10.1016/j.jacc.2007.01.079.
    1. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet. 2002;359:881–884. doi: 10.1016/S0140-6736(02)07948-5.
    1. Ashley EA, Myers J, Froelicher V. Exercise testing in clinical medicine. Lancet. 2000;356:1592–1597. doi: 10.1016/S0140-6736(00)03138-X.
    1. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Mooss AN, O'Reilly MG, Winters WL. , JrACC/AHA 2002 guideline update for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing) American College of Cardiology. 2002.
    1. Barett EJ, Ginsberg HN, Pauker SG, Rutherford JD, Smith SC, Young LH, Zimmerman BR. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes. Diabetes Care. 1998;21:1551–1559. doi: 10.2337/diacare.21.9.1551.
    1. Fowler-Brown A, Pignone M, Pletcher M, Tice JA, Sutton SF, Lohr KN. Exercise Tolerance Testing To Screen for Coronary Heart Disease: A Systematic Review for the Technical Support for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140:W9–W24.
    1. Mehta SR, Eikelboom JW, Demers C, Maggioni AP, Commerford PJ, Yusuf S. Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. Can J Physiol Pharm. 2005;83:98–103. doi: 10.1139/y05-003.
    1. Il Progetto Cuore.
    1. Calmieri L, Vanuzzo D, Panico S, Ferrario M, Giampaoli S. a nome del Gruppo di Ricerca del Progetto CUORE - Studi Longitudinali. La strategia dell'alto rischio. Il rischio di primo evento cardiovascolare maggiore negli uomini. Ital Heart J. 2004;5:54s–58s.
    1. Levey AS, Greene T, Kusek JW, Beck GL. MDRD Study Group. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract] J Am Soc Nephrol. 2000;11:155A.
    1. .
    1. The task force on Diabetes and Cardiovascular Diseases of European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J. 2007;28:88–136. doi: 10.1093/eurheartj/ehl260.
    1. Gulati M, Black HR, Shaw LJ, Arnsdorf MF, Merz NB, Lauer MS, Marwick TH, Pandey DK, Wicklund RH, Thisted RA. The prognostic value for exercise capacity in woman. N Engl J Med. 2005;353:468–475. doi: 10.1056/NEJMoa044154.
    1. Bacci S, Villella M, Villella A, Langialonga T, Grilli M, Rauseo A, Mastroianno S, De Cosmo S, Fanelli R, Trischitta V. Screening for silent myocardial ischemia in type 2 diabetic patients with additional atherogenic risk factors: applicability and accuracy of the exercise stress test. Eur J Endocrinol. 2002;147:649–654. doi: 10.1530/eje.0.1470649.
    1. Faglia E, Favales F, Calia P, Paleari F, Segalini G, Gamba PL, Rocca A, Musacchio N, Mastropasqua A, Testori G, Rampini P, Moratti F, Braga A, Morabito A. Cardiac Events in 735 type 2 diabetic patients who underwent screening for unknown coronary heart disease. Diabetes Care. 2002;25:2032–2036. doi: 10.2337/diacare.25.11.2032.
    1. Bourassa MG, Knatterud GL, Pepine CJ, Sopko G, Rogers WJ, Geller NL, Dyrda I, Forman SA, Chaitman BR, Sharaf B, Davies RF, Conti R. for the ACIP Investigators. Asymptomatic Cardiac Ischemia Pilot (ACIP) Study - Improvement of Cardiac Ischemia at 1 year after PTCA and CABG. Circulation. 1995;92:1–7.
    1. Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, Spila-Alegian S, Turco S, Velassi M, Ferrannini E. for the Diabetes and Informatics Study Group, Association of Clinical Diabetologists, Istituto Superiore di Sanità. Incidence of Coronary Heart Disease in Type 2 Diabetic Men and Women. Diabetes Care. 2007;30:1241–1247. doi: 10.2337/dc06-2558.
    1. Rosner B. Fundamentals of Biostatistics. Sixth. Cengage Learning; 2006. Hypothesis testing - Estimation of Sample Size and Power for Comparing Two Means; pp. 416–426.
    1. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Third. New York, USA: Oxford University Press; 2005.
    1. CONSORT - Trasparent Reporting of Trials.
    1. Young LH, Wackers FJT, Chyun DA, Davey JA, Barret EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE. Cardiac Outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes. JAMA. 2009;301:1547–1555. doi: 10.1001/jama.2009.476.
    1. The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–2515. doi: 10.1056/NEJMoa0805796.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit